Vivos Therapeutics Extends Critical $2.6M Financing Deadline to August 31st
VVOS is trading near its 52-week low of $0.383 (13% above the low) on light trading volume (0.1× avg).
Summary
Vivos Therapeutics has extended the deadline to complete a qualifying financing of at least $2.6 million from June 15, 2026, to August 31, 2026. This follows the company's recent agreements in early June to convert up to $4.5 million of senior debt into equity with Streeterville Capital, a move aimed at reducing leverage. The company has repeatedly issued 'going concern' warnings, reported significant cash burn in Q1 2026, and received a Nasdaq non-compliance notice for minimum stockholders' equity. The extension provides Vivos with additional time to secure the vital $2.6 million financing, which is critical for its liquidity and continued operations given its precarious financial state. The market will now focus on whether the company can secure this financing by the new August 31st deadline.
At the time of this announcement, VVOS was trading at $0.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $0.38 to $7.95. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.